Form 4: GoodRx CFO Karsten Voermann Reports Acquisition of Restricted Stock Units and Stock Options

Karsten Voermann, CFO of GoodRx Holdings, Inc., reports the acquisition of restricted stock units and stock options, increasing his beneficial ownership in the company.

Summary

• On March 12, 2024, Karsten Voermann, the Chief Financial Officer of GoodRx Holdings, Inc., reported transactions involving derivative securities.
• Voermann acquired 357,168 Restricted Stock Units (RSUs) which each represent a contingent right to receive one share of Class A common stock.
• These RSUs will vest as to 25% of the underlying shares on January 8, 2025, with the remaining 75% vesting in approximately equal quarterly installments over the following 12 quarters.
• Voermann also acquired 515,793 stock options with an exercise price of $7.22.
• These options will vest as to 25% of the underlying shares on January 8, 2025, with the remaining 75% vesting in approximately equal quarterly installments over the following 12 quarters, and expire on March 12, 2034.
• Following these transactions, Voermann directly owns 211,952 shares of Class A Common Stock, 357,168 RSUs, and 515,793 stock options.

Sentiment

Score: 6

Explanation: The document is a standard regulatory filing detailing executive compensation. It doesn't inherently convey strong positive or negative sentiment, but the acquisition of equity could be interpreted as a mild positive signal of the executive's confidence in the company.

Positives

• The acquisition of RSUs and stock options by the CFO could be seen as a positive sign, indicating confidence in the company's future performance.

Industry Context

This filing is a routine disclosure of insider transactions, which are common in publicly traded companies. It provides transparency into the holdings and transactions of company executives.

Comparison to Industry Standards

• Equity compensation in the form of RSUs and stock options is a standard practice among publicly traded companies, particularly in the tech and healthcare sectors, to incentivize and retain key executives.
• Vesting schedules, such as the one described (25% after one year, then quarterly), are also typical in the industry.
• Companies like Teladoc Health and CVS Health also utilize similar equity compensation strategies for their executives.

Stakeholder Impact

• The transactions could have a minor positive impact on shareholder sentiment if viewed as a sign of the CFO's confidence in the company's future.

Key Dates